The CooperCOO +0.48%89 PS Ratio is 3.31 as of Jun. 28, 2026, which is 37% below its 10-year median of 5.25. GuruFocus rates COO with a GF Score™ of 89/100 and a GF Value™ of $100.88 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 805 Medical Devices & Instruments companies, The Cooper ranks worse than 56.15% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, The Cooper's share price is $71.02.
The Cooper's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 was $21.43. Hence, The Cooper's PS Ratio for today is 3.31.
The historical rank and industry rank for The Cooper's PS Ratio or its related term are showing as below:
COO'
s PS Ratio Range Over the Past 10 Years
Min: 2.78 Med: 5.25 Max: 8.28
Current: 3.31
During the past 13 years, The Cooper's highest PS Ratio was 8.28. The lowest was 2.78. And the median was 5.25.
COO's PS Ratio is ranked worse than 56.15% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.87
vs COO: 3.31
The Cooper Companies Inc has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of The Cooper was 7.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 7.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 10.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 8.40% per year.
During the past 13 years, The Cooper's highest 3-Year average Revenue per Share Growth Rate was 30.80% per year. The lowest was -62.60% per year. And the median was 8.20% per year.
Back to Basics: PS Ratio
The Cooper (NAS:COO) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
The Cooper PS Ratio Related Terms
The Cooper PS Ratio Historical Data
* Premium members only.
The historical data trend for The Cooper's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, The Cooper's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's PS Ratio distribution charts can be found below:
* The bar in red indicates where The Cooper's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
The Cooper's Share Price of today is $71.02. The Cooper's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $21.43.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
The Cooper (COO) has a PS Ratio of 3.31 as of Jun. 28, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on The Cooper and its competitors. This is 37% below median its historical median of 5.25. Over the past decade, The Cooper's PS Ratio has ranged from 2.78 to 8.28. According to the industry distribution chart, The Cooper ranks #452 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 56.1%.
Is The Cooper's PS Ratio too high?
The Cooper's current PS Ratio of 3.31 is 37% below median its 10-year median of 5.25. Over the past 10 years, this metric has ranged from a low of 2.78 to a high of 8.28. The Medical Devices & Instruments industry median PS Ratio is 2.87. The Cooper's value of 3.31 is 15.3% above this industry median. Based on the distribution chart, The Cooper ranks #452 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, The Cooper has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's PS Ratio compare to ALGN and SOLV?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #452 out of 805 companies for PS Ratio. This places The Cooper in the lower half of its industry. The industry median PS Ratio is 2.87. The Cooper's value of 3.31 is 15.3% above this benchmark. Historically, The Cooper's own PS Ratio has ranged from 2.78 to 8.28 over the past decade. While the company's 10-year median is 5.25 vs. the industry median of 2.87, The Cooper has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.87, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Cooper's current PS Ratio of 3.31 is 15.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current PS Ratio is 3.31, which is 37% below median its own 10-year median of 5.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Significantly Undervalued. The stock's GF Value™ is $100.88, compared to a current price of $71.02 — trading 29.6% below its estimated fair value. The current PS Ratio is 3.31, which is 37% below median its 10-year median of 5.25 and 15.3% above the Medical Devices & Instruments industry median of 2.87. The Cooper's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For The Cooper (COO), the current PS Ratio is 3.31 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $71.02 is trading 29.6% below its estimated GF Value™ of $100.88.
GuruFocus considers The Cooper to be Significantly Undervalued.
Key valuation signals for COO:
PS Ratio: 3.31 (37% below median its 10-year median of 5.25)
GF Value™: $100.88 vs. price of $71.02 (29.6% below fair value)
Industry Position: 15.3% above the Medical Devices & Instruments median (#452 of 805)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
89GF Score
Get the complete analysis for COO
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
